Opendata, web and dolomites


The first effective remedy for acute pancreatitis disease

Total Cost €


EC-Contrib. €






 RAPID project word cloud

Explore the words cloud of the RAPID project. It provides you a very rough idea of what is the project "RAPID" about.

people    gastroenterology    small    patented    2024    solution    solutions    trigger    39    license    orphan    chemicare    paths    spin    dossier    hyper    endoscopic    pharmacological    muscular    accelerated    room    capacity    therapeutic    clinical    myopathy    ema    prior    overload    phases    frame    modulate    time    emergency    providers    optimal    yearly    breakthrough    revenues    undergo    molecules    tubular    validate    calcium    plan    ready    care    health    proved    utmost    regulatory    piemonte    services    diseases    prepare    validation    position    generating    innovation    orientale    cluster    initiation    pharma    patients    last    entry    reinvested    admitted    globally    market    surgical    ions    drug    discharge    trials    therapies    healthcare    advantage    pancreatitis    rapid    preclinically    visits    complete    pave    rare    hospitalizations    university    diagnosis    designation    indications    frequent    aggregate    preclinical    ap    duchenne    acute    candidate    company    cellular    store    costing    data    national    million    fda    dystrophy    burden    operated    tech    off    disease    intensive    activation    finance   

Project "RAPID" data sheet

The following table provides information about the project.


Organization address
address: VIA AMICO CANOBIO 4/6
city: NOVARA
postcode: 28100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-10-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CHEMICARE SARL IT (NOVARA) coordinator 50˙000.00


 Project objective

ChemICare is a high-tech spin-off of the University of Piemonte Orientale and has patented and preclinically developed small molecules that are unique in their capacity to modulate calcium ions uptake in cellular processes. Calcium overload associated with Store-Operated Calcium Entry hyper-activation has been proved to be to be the key trigger in a cluster of diseases, including Acute Pancreatitis, which affects over 10 million people globally and is the most common gastroenterology discharge diagnosis in Europe and the US. AP is associated with significant disease burden, emergency room visits, frequent hospitalizations, and patients often undergo endoscopic and surgical procedures and are admitted to intensive care, costing more than 20 B€ yearly to National Healthcare Services. Preclinical data obtained so far demonstrate that drug candidate 39 represents a breakthrough innovation in the field of pharmacological therapies for AP. We are now in the process of generating the last data to complete the preclinical regulatory dossier, which will pave the way for the Phase I and II clinical trials which will lead to an out-license agreement to a large pharma company prior to the initiation of Phase III. The revenues will therefore be reinvested to finance development of the same technology for other therapeutic indications associated with calcium overload (e.g. Duchenne Muscular Dystrophy and Tubular Aggregate Myopathy). This Phase 1 is of utmost importance to validate the market position of ChemICare molecules, apply for orphan designation, and plan the preclinical study necessary to prepare the clinical validation Phases in the frame of the Phase 2. Our goal is to have a solution ready for the market by 2024, which will be cost-effective for health providers and deliver optimal care to patients with AP. Such rapid time-to-market is possible because both EMA and FDA have accelerated paths for rare disease solutions that we will take advantage of.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RAPID" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RAPID" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

QCAUX (2020)

Optimised auxiliary electronics system for quantum computing research

Read More  


Specialized Help from Be My Eyes – harnessing technology to connect companies directly with their blind and visually impaired users

Read More  

Manuback (2019)

MANUBACK, the smart garment for operator protection in the field of Manual Handling of Goods

Read More